StaphVAX vaccine of type 5 and 8 capsular polysaccharide conjugate data

NABI announced interim results from an ongoing Phase II trial of StaphVAX, showing that the anti-staph vaccine was well tolerated and stimulated antibodies for at least three months in patients with e...